Testing ifinatamab deruxtecan against docetaxel in advanced prostate cancer
Compares a study medicine with chemotherapy in men with advanced prostate cancer.
Key facts
- Who runs it
- Merck Sharp & Dohme LLC
- Where
- Albuquerque, Ann Arbor, Atlanta, Aurora, Baltimore, Billings, Boston, Chicago, Clermont, Clovis, Columbus, Dallas, Detroit, Duarte, Grand Island, Grand Rapids, Hackensack, Houston, Irvine, Jacksonville, La Jolla, Las Vegas, Lexington, Long Beach, Los Angeles, Madison, Memphis, Milwaukee, Nashville, New Haven, New York, Omaha, Orange, Orange City, Palo Alto, Philadelphia, Phoenix, Portland, Roanoke, Rochester, Saint Louis Park, Saint Paul, Seattle, Washington D.C., West Haven, and Williamsville, United StatesSee the 55 sitesAlso in 34 other countries, 246 sites
- Trial code
- NCT06925737
- EU 2024-517423-40-00
- U1111-1312-2498
- Registry title
- A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 1,440 people, planned
- Started
- 13 May 2025
- Expected to end
- 6 Jan 2031
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Ifinatamab deruxtecan
- Docetaxel
- Prednisone
- Rescue Medication
- Record updated
- 30 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men with prostate cancer that has spread and no longer responds to hormone-lowering treatment. It compares ifinatamab deruxtecan with docetaxel chemotherapy.
- Age
- 18 years or older
- Sex
- Men only
- Disease stage
- Prostate adenocarcinoma (not small cell) that has spread to distant sites, with growth despite androgen deprivation therapy within the last 6 months
- Earlier treatment
- Must have had 1 or 2 androgen receptor pathway inhibitors and progressed during or after at least 8 weeks of treatment. Must not have had taxane chemotherapy for metastatic castration-resistant prostate cancer.
- Biomarker or test result
- A tumor tissue sample from a soft tissue biopsy, not previously irradiated and taken after the latest progression, must be provided
Main reasons for not taking part
- Cannot swallow tablets or capsules
- Past or current interstitial lung disease or pneumonitis that needed steroids
- Severe lung problems from other lung illnesses
- Uncontrolled or significant heart or blood vessel disease
- Stopped an earlier exatecan-derivative antibody drug conjugate (such as trastuzumab deruxtecan) because of side effects
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- The main inclusion criteria include but are not limited to the following:
- Has histologically- or cytologically-confirmed adenocarcinoma of the prostate without small cell histology
- Has prostate cancer progression while on androgen deprivation therapy (ADT) (or post bilateral orchiectomy) within 6 months prior to Screening
- Has current evidence of distant metastatic disease (M1 disease) documented by either bone lesions on bone scan and/or soft tissue disease by computed tomography (CT)/magnetic resonance imaging (MRI)
- Has received prior treatment with 1 or 2 androgen receptor pathway inhibitors (ARPIs) and progressed during or after at least 8 weeks of treatment
- Has provided tumor tissue from a core or excisional biopsy from soft tissue not previously irradiated and obtained after disease progression on the most recent prior therapy
- Has recovered from adverse events (AEs) due to previous anticancer therapies
Who cannot take part
- Has received prior treatment with a taxane-based chemotherapy agent for metastatic castration-resistant prostate cancer (mCRPC)
- Has had prior discontinuation of an antibody drug conjugate (ADC) that consists of an exatecan derivative (eg, trastuzumab deruxtecan) due to treatment-related toxicities
- Has any of the following indicators of interstitial lung disease (ILD)/pneumonitis:; Has any history of ILD/pneumonitis that required steroid use, except for a history of radiation pneumonitis that did not require steroids; Has current ILD/pneumonitis; Has a clinical or radiographic suspicion of ILD for which the diagnosis of ILD cannot be ruled out
- Has clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses
- Has uncontrolled or significant cardiovascular disease
- The main exclusion criteria include but are not limited to the following:
- Is unable to swallow tablets/capsules
- Has a "superscan" bone scan
Where in United States
Also in 34 other countries, 246 sites
- University of New Mexico Comprehensive Cancer Center (Site 0022)Albuquerque, United StatesContact: Study CoordinatorTaking people
- University of Michigan (Site 0005)Ann Arbor, United StatesContact: Study CoordinatorTaking people
- Emory University School of Medicine- Grady Campus (Site 0103)Atlanta, United StatesContact: Study CoordinatorTaking people
- Winship Cancer Institute, Emory University (Site 0003)Atlanta, United StatesContact: Study CoordinatorTaking people
- Rocky Mountain Regional Veterans Affairs Medical Center (Site 0053)Aurora, United StatesContact: Study CoordinatorTaking people
- Greenebaum Comprehensive Cancer Center (Site 0021)Baltimore, United StatesContact: Study CoordinatorTaking people
- St. Vincent Frontier Cancer Center-Research (Site 0037)Billings, United StatesContact: Study CoordinatorTaking people
- Beth Israel Deaconess Medical Center (Site 0043)Boston, United StatesContact: Study CoordinatorTaking people
- Dana Farber Cancer Institute (Site 0012)Boston, United StatesContact: Study CoordinatorTaking people
- Rush University Medical Center-Hematology and Oncology (Site 0028)Chicago, United StatesContact: Study CoordinatorTaking people
- University of Illinois at Chicago-University of Illinois Cancer Center (Site 0063)Chicago, United StatesContact: Study CoordinatorTaking people
- Clermont Oncology Center (Site 0087)Clermont, United StatesContact: Study CoordinatorTaking people
- Community Cancer Institute (Site 0081)Clovis, United StatesContact: Study CoordinatorTaking people
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C (Site 0061)Columbus, United StatesContact: Study CoordinatorTaking people
- Parkland Health & Hospital System (Site 0069)Dallas, United StatesContact: Study CoordinatorTaking people
- UT Southwestern Medical Center (Site 0039)Dallas, United StatesContact: Study CoordinatorTaking people
- Henry Ford Hospital (Site 0035)Detroit, United StatesContact: Study CoordinatorTaking people
- City of Hope Comprehensive Cancer Center (Site 0049)Duarte, United StatesContact: Study CoordinatorTaking people
- Oncology Hematology West, PC dba Nebraska Cancer Specialists - Grand Island (Site 0076)Grand Island, United StatesContact: Toll Free NumberNo longer taking part
- Cancer and Hematology Centers of Western Michigan (Site 0015)Grand Rapids, United StatesContact: Study CoordinatorTaking people
- John Theurer Cancer Center at Hackensack University Medical Center (Site 0016)Hackensack, United StatesContact: Study CoordinatorTaking people
- University of Texas-MD Anderson Cancer Center (Site 0055)Houston, United StatesContact: Study CoordinatorTaking people
- City of Hope Lennar Foundation Cancer Center (Site 0059)Irvine, United StatesContact: Study CoordinatorTaking people
- Mayo Clinic in Florida-Mayo Clinic Comprehensive Cancer Center (Site 0077)Jacksonville, United StatesContact: Study CoordinatorTaking people
- Moores Cancer Center (Site 0010)La Jolla, United StatesContact: Study CoordinatorTaking people
- Comprehensive Cancer Centers of Nevada (Site 0082)Las Vegas, United StatesContact: Study CoordinatorTaking people
- University of Kentucky Chandler Medical Center (Site 0048)Lexington, United StatesContact: Study CoordinatorTaking people
- Veterans Affairs Long Beach Healthcare System (Site 0058)Long Beach, United StatesContact: Study CoordinatorTaking people
- Cedars-Sinai Medical Center (Site 0068)Los Angeles, United StatesContact: Study CoordinatorTaking people
- UCLA Hematology/Oncology - Santa Monica (Site 0002)Los Angeles, United StatesContact: Study CoordinatorTaking people
- University Hospital and UW Health Clinics (Site 0065)Madison, United StatesContact: Study CoordinatorTaking people
- Memphis VA Medical Center (Site 0072)Memphis, United StatesContact: Study CoordinatorTaking people
- Medical College of Wisconsin (Site 0008)Milwaukee, United StatesContact: Study CoordinatorTaking people
- Henry-Joyce Cancer Clinic (Site 0042)Nashville, United StatesContact: Study CoordinatorTaking people
- SCRI Oncology Partners (Site 0074)Nashville, United StatesContact: Study CoordinatorTaking people
- Yale-New Haven Hospital-Yale Cancer Center (Site 0050)New Haven, United StatesContact: Study CoordinatorTaking people
- Icahn School of Medicine at Mount Sinai (Site 0009)New York, United StatesContact: Study CoordinatorTaking people
- Oncology Hematology West P.C. dba Nebraska Cancer Specialists (Site 0026)Omaha, United StatesContact: Toll Free NumberNo longer taking part
- University of California, Irvine (UCI) Health - UC Irvine Medical Center (Site 0006)Orange, United StatesContact: Study CoordinatorTaking people
- Mid Florida Hematology and Oncology Center (Site 0086)Orange City, United StatesContact: Study CoordinatorTaking people
- Stanford Cancer Center (Site 0046)Palo Alto, United StatesContact: Study CoordinatorTaking people
- Abramson Cancer Center - Penn Medicine (Site 0079)Philadelphia, United StatesContact: Study CoordinatorTaking people
- Perelman Center for Advanced Medicine (Site 0067)Philadelphia, United StatesContact: Study CoordinatorTaking people
- Mayo Clinic in Arizona - Phoenix (Site 0044)Phoenix, United StatesContact: Study CoordinatorTaking people
- VA Portland Health Care System (Site 0038)Portland, United StatesContact: Study CoordinatorTaking people
- Blue Ridge Cancer Care (Site 0024)Roanoke, United StatesContact: Toll Free NumberNo longer taking part
- Mayo Clinic in Rochester, Minnesota-Mayo Clinic Comprehensive Cancer Center (Site 0078)Rochester, United StatesContact: Study CoordinatorTaking people
- HealthPartners Cancer Research Center-HealthPartners Frauenshuh Cancer Center (Site 0032)Saint Louis Park, United StatesContact: Study CoordinatorTaking people
- HealthPartners Cancer Center at Regions Hospital (Site 0052)Saint Paul, United StatesContact: Study CoordinatorTaking people
- Fred Hutchinson Cancer Center (Site 0060)Seattle, United StatesContact: Study CoordinatorTaking people
- VA Puget Sound Health Care System (Site 0054)Seattle, United StatesContact: Study CoordinatorTaking people
- Washington DC Veterans Affairs Medical Center (Site 0056)Washington D.C., United StatesContact: Study CoordinatorTaking people
- The GW Medical Faculty Associates (Site 0057)Washington D.C., United StatesContact: Toll Free NumberNo longer taking part
- Veterans Affairs Connecticut Healthcare System (Site 0062)West Haven, United StatesContact: Study CoordinatorTaking people
- Great Lakes Cancer Care (Site 0047)Williamsville, United StatesContact: Study CoordinatorTaking people
About the trial
What the trial wants to find out
Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this study is to learn if people who receive I-DXd live longer overall and live longer without the cancer growing or spreading than people who receive chemotherapy.
The 2 groups in the trial
- I-DXdTreatment being tested
Participants receive I-DXd 12mg/kg every 3 weeks (q3w)
Treatment: Ifinatamab deruxtecan and Rescue Medication
- DocetaxelExisting treatment, for comparison
Participants receive docetaxel 75 mg/m\^2 q3w and prednisone 10 mg/day or per approved product label
Treatment: Docetaxel and Prednisone
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (IDeate-Prostate01)
- Plain-language title
- Testing ifinatamab deruxtecan against docetaxel in advanced prostate cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 30 October 2026